{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T19:55:12Z","timestamp":1781812512183,"version":"3.54.5"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T00:00:00Z","timestamp":1775260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T00:00:00Z","timestamp":1775260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100009015","name":"Abbott Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009015","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Interv and Ther"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s12928-026-01266-2","type":"journal-article","created":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T16:27:57Z","timestamp":1775320077000},"page":"574-585","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Aspirin versus clopidogrel beyond 1\u00a0month after percutaneous coronary intervention in high bleeding risk patients with or without acute coronary syndrome: a subgroup analysis from the STOPDAPT-3 trial"],"prefix":"10.1007","volume":"41","author":[{"given":"Tetsuya","family":"Ishikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Natsuaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotoshi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ko","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Obayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryusuke","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Suwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Isawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Takenaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Ikari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tairo","family":"Kurita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Kaitani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuhiko","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiko","family":"Ogata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Ikuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsushi","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Ishibashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Miyabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koh","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5665-4076","authenticated-orcid":false,"given":"Takeshi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,4]]},"reference":[{"key":"1266_CR1","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","volume":"44","author":"RA Byrne","year":"2023","unstructured":"Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44:3720\u2013826.","journal-title":"Eur Heart J"},{"key":"1266_CR2","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","volume":"45","author":"C Vrints","year":"2024","unstructured":"Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024;45:3415\u2013537.","journal-title":"Eur Heart J"},{"key":"1266_CR3","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1253\/circj.CJ-21-0016","volume":"85","author":"M Natsuaki","year":"2021","unstructured":"Natsuaki M, Morimoto T, Shiomi H, Kadota K, Tada T, Takeji Y, et al. Effects of acute coronary syndrome and stable coronary artery disease on bleeding and ischemic risk after percutaneous coronary intervention. Circ J. 2021;85:1928\u201341.","journal-title":"Circ J"},{"key":"1266_CR4","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1056\/NEJMoa2108749","volume":"385","author":"M Valgimigli","year":"2021","unstructured":"Valgimigli M, Frigoli E, Heg D, Tijssen J, Juni P, Vranckx P, et al. Dual antiplatelet therapy after PCI in patients at high bleeding risk. N Engl J Med. 2021;385:1643\u201355.","journal-title":"N Engl J Med"},{"key":"1266_CR5","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1161\/CIRCULATIONAHA.123.066720","volume":"149","author":"M Natsuaki","year":"2024","unstructured":"Natsuaki M, Watanabe H, Morimoto T, Yamamoto K, Obayashi Y, Nishikawa R, et al. An Aspirin-Free Versus Dual Antiplatelet Strategy for Coronary Stenting: STOPDAPT-3 Randomized Trial. Circulation. 2024;149:585\u2013600.","journal-title":"Circulation"},{"key":"1266_CR6","doi-asserted-by":"publisher","first-page":"5042","DOI":"10.1093\/eurheartj\/ehae617","volume":"45","author":"H Watanabe","year":"2024","unstructured":"Watanabe H, Natsuaki M, Morimoto T, Yamamoto K, Obayashi Y, Nishikawa R, et al. Aspirin vs. clopidogrel monotherapy after percutaneous coronary intervention: 1-year follow-up of the STOPDAPT-3 trial. Eur Heart J. 2024;45:5042\u201354.","journal-title":"Eur Heart J"},{"issue":"25","key":"1266_CR7","first-page":"00950","volume":"S1936\u20138798","author":"Y Obayashi","year":"2025","unstructured":"Obayashi Y, Natsuaki M, Watanabe H, Morimoto T, Yamamoto K, Nishikawa R, et al. Aspirin versus clopidogrel 1 month after acute coronary syndrome with high-bleeding risk or ST-segment elevation. JACC Cardiovasc Interv. 2025;S1936\u20138798(25):00950\u20131.","journal-title":"JACC Cardiovasc Interv"},{"key":"1266_CR8","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","volume":"123","author":"R Mehran","year":"2011","unstructured":"Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123:2736\u201347.","journal-title":"Circulation"},{"key":"1266_CR9","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1016\/S0140-6736(21)01063-1","volume":"397","author":"BK Koo","year":"2021","unstructured":"Koo BK, Kang J, Park KW, Rhee TM, Yang HM, Won KB, et al. Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): An investigator-initiated, prospective, randomised, open-label, multicentre trial. Lancet. 2021;397:2487\u201396.","journal-title":"Lancet"},{"key":"1266_CR10","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jacc.2023.04.051","volume":"82","author":"F Gragnano","year":"2023","unstructured":"Gragnano F, Cao D, Pirondini L, Franzone A, Kim HS, von Scheidt M, et al. P2Y12 inhibitor or aspirin monotherapy for secondary prevention of coronary events. J Am Coll Cardiol. 2023;82:89\u2013105.","journal-title":"J Am Coll Cardiol"},{"key":"1266_CR11","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/S0140-6736(25)00449-0","volume":"405","author":"KH Choi","year":"2025","unstructured":"Choi KH, Park YH, Lee JY, Jeong JO, Kim CJ, Yun KH, et al. Efficacy and safety of clopidogrel versus aspirin monotherapy in patients at high risk of subsequent cardiovascular event after percutaneous coronary intervention (SMART-CHOICE 3): A randomised, open-label, multicentre trial. Lancet. 2025;405:1252\u201363.","journal-title":"Lancet"},{"key":"1266_CR12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jacc.2023.10.013","volume":"83","author":"H Watanabe","year":"2024","unstructured":"Watanabe H, Morimoto T, Natsuaki M, Yamamoto K, Obayashi Y, Nishikawa R, et al. Clopidogrel vs aspirin monotherapy beyond 1 year after percutaneous coronary intervention. J Am Coll Cardiol. 2024;83:17\u201331.","journal-title":"J Am Coll Cardiol"},{"key":"1266_CR13","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S0140-6736(25)01562-4","volume":"406","author":"M Valgimigli","year":"2025","unstructured":"Valgimigli M, Choi KH, Giacoppo D, Gragnano F, Kimura T, Watanabe H, et al. Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysis. Lancet. 2025;406:1091\u2013102.","journal-title":"Lancet"},{"key":"1266_CR14","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1253\/circj.CJ-13-1482","volume":"78","author":"S Saito","year":"2014","unstructured":"Saito S, Isshiki T, Kimura T, Ogawa H, Yokoi H, Nanto ST, et al. Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study. Circ J. 2014;78:1684\u201392.","journal-title":"Circ J"},{"key":"1266_CR15","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/S0140-6736(24)01616-7","volume":"404","author":"M Valgimigli","year":"2024","unstructured":"Valgimigli M, Hong SJ, Gragnano F, Chalkou K, Franzone A, da Costa BR, et al. De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials. Lancet. 2024;404:937\u201348.","journal-title":"Lancet"}],"container-title":["Cardiovascular Intervention and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12928-026-01266-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12928-026-01266-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12928-026-01266-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T19:04:48Z","timestamp":1781809488000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12928-026-01266-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,4]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1266"],"URL":"https:\/\/doi.org\/10.1007\/s12928-026-01266-2","relation":{},"ISSN":["1868-4300","1868-4297"],"issn-type":[{"value":"1868-4300","type":"print"},{"value":"1868-4297","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,4]]},"assertion":[{"value":"28 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr Natsuaki reports honoraria from Abbott Medical Japan, Daiichi Sankyo, Medtronic, Terumo, Japan Lifeline, Asahi Intecc, Bristol-Myers Squibb, Otsuka, Amgen, Sanofi, Takeda and Bayer. Dr Watanabe reports personal fees from Abbott Medical Japan during the conduct of the study as well as personal fees from Daiichi Sankyo, Kowa, Abiomed, Bayer, Pfizer, Bristol-Myers Squibb, and Otsuka outside the submitted work. Dr. Morimoto reports lecturers fees from AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, Japan Lifeline, Kowa, Pfizer and Tsumura; manuscript fees from Bristol-Myers Squibb and Pfizer; advisory board for Novartis and Teijin. Dr Obayashi reports honoraria from Abbott Medical Japan. Dr Kimura reports grants from Abbott Medical Japan and Boston Scientific and being an advisory board member of Abbott Medical Japan and Terumo Japan. No other disclosures were reported.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}